{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:49Z","timestamp":1793679229488,"version":"4.5.1"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec id=\"ab-noi250056-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Developing disease-modifying treatments is a priority for Alzheimer disease research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250056-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the potential of plasma phosphorylated tau 217 (p-tau217) and tau positron emission tomography (PET) to assess disease modification in treatment trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250056-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This diagnostic\/prognostic study used longitudinal data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s Disease (A4) study collected from April 2014 to June 2023. Recruited from 67 sites in the US, Canada, Australia, and Japan, participants included older individuals (age 65-85 years) who were cognitively unimpaired at screening and underwent an amyloid PET scan. Participants without elevated amyloid PET were included from a companion to the A4 study, the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250056-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetapir PET imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250056-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetapir PET imaging was used to classify participants as having elevated amyloid \u03b2 (A\u03b2+). Measures of tau included longitudinal plasma p-tau217 and\n                      <jats:sup>18<\/jats:sup>\n                      F-flortaucipir PET. Cognition was assessed using the Preclinical Alzheimer Cognitive Composite (PACC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250056-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1169 individuals were included from A4 Study and 538 without elevated amyloid PET were included from the LEARN Study. Among these 1707 participants, the baseline mean (SD) age was 71.5 (4.7) years, 1024 (60%) were female, and 683 (40%) male; 1169 participants were A\u03b2+, and the mean (SD) Mini-Mental State Examination score was 28.8 (1.2). The tau PET substudy included 443 participants; plasma p-tau217 levels were available for 1643 participants. The largest effect size of longitudinal tau PET accumulation at 36 months in A\u03b2+ participants was in the inferior temporal gyrus. Baseline associations with longitudinal change in PACC score in A\u03b2+ participants were strongest in the entorhinal cortex (correlation [\u03c1]\u2009=\u2009\u22120.55; 95% CI, \u22120.63 to \u22120.45) and plasma p-tau217 levels (\u03c1\u2009=\u2009\u22120.47; 95% CI, \u22120.56 to \u22120.37). Tau PET changes in frontoparietal regions were strongly correlated with concurrent cognitive changes. Levels of plasma p-tau217 increased significantly in A\u03b2+ participants before showing significant deceleration (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200921.7;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and were not associated with concurrent cognitive change in the tau PET substudy (\u03c1\u2009=\u2009\u22120.03; 95% CI, \u22120.23 to 0.16) but were modestly associated with concurrent cognitive changes in the full plasma sample (n\u2009=\u20091119; \u03c1\u2009=\u2009\u22120.24; 95% CI, \u22120.34 to \u22120.14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-noi250056-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This study found that tau PET is valuable for both prognostic and real-time tracking of disease progression. Plasma p-tau217 predicts cognitive changes prior to overt cognitive impairment and can efficiently guide participant selection. Imaging-based tau measures may enhance detection of disease-modifying effects and refine therapeutic targets in future Alzheimer disease trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.2974","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T15:31:03Z","timestamp":1756135863000},"page":"985","source":"Crossref","is-referenced-by-count":34,"title":["Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease"],"prefix":"10.1001","volume":"82","author":[{"given":"Philip S.","family":"Insel","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Langford","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent M.","family":"Caruso","sequence":"additional","affiliation":[{"name":"Convergent Genomics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Leuzy","sequence":"additional","affiliation":[{"name":"Banner Alzheimer\u2019s Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Boxer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Neurology, Harvard Aging Brain Study, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Mormino","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford University, Stanford, California"},{"name":"Wu Tsai Neurosciences Institute, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Donohue","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi250056r1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14283\/jpad.2017.12","article-title":"Defining disease modifying therapy for Alzheimer\u2019s disease.","volume":"4","author":"Cummings","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"noi250056r2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jspi.2007.06.005","article-title":"The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials.","volume":"138","author":"Molenberghs","year":"2008","journal-title":"J Stat Plan Inference"},{"issue":"2","key":"noi250056r3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3233\/JAD-231198","article-title":"Substantial doubt remains about the efficacy of anti-amyloid antibodies.","volume":"97","author":"Digma","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"noi250056r4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jamaneurol.2023.0815","article-title":"Advocating for demonstration of disease modification: have we been approaching clinical trials in early Alzheimer disease incorrectly?","volume":"80","author":"Planche","year":"2023","journal-title":"JAMA Neurol"},{"issue":"4","key":"noi250056r5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s11222-020-09927-9","article-title":"Joint models with multiple longitudinal outcomes and a time-to-event outcome: a corrected two-stage approach.","volume":"30","author":"Mauff","year":"2020","journal-title":"Stat Comput"},{"issue":"1","key":"noi250056r7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"noi250056r8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"noi250056r10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","article-title":"Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment.","volume":"15","author":"Mundada","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi250056r11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers.","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol"},{"issue":"4","key":"noi250056r12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14283\/jpad.2024.122","article-title":"Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies.","volume":"11","author":"Sperling","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"noi250056r14","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup.","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8","key":"noi250056r15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study.","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"issue":"12","key":"noi250056r16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer\u2019s disease.","volume":"389","author":"Sperling","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"noi250056r17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals.","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi250056r18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease.","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"noi250056r19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.14283\/jpad.2024.134","article-title":"Longitudinal phospho-tau217 predicts amyloid positron emission tomography in asymptomatic Alzheimer\u2019s disease.","volume":"11","author":"Rissman","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"8","key":"noi250056r20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol"},{"issue":"2","key":"noi250056r22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/rssa.12378","article-title":"Visualization in Bayesian workflow.","volume":"182","author":"Gabry","year":"2019","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"2","key":"noi250056r23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/brain\/awac299","article-title":"Tau positron emission tomography in preclinical Alzheimer\u2019s disease.","volume":"146","author":"Insel","year":"2023","journal-title":"Brain"},{"issue":"12","key":"noi250056r24","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.neuron.2022.03.034","article-title":"Regional A\u00df-tau interactions promote onset and acceleration of Alzheimer\u2019s disease tau spreading.","volume":"110","author":"Lee","year":"2022","journal-title":"Neuron"},{"issue":"2","key":"noi250056r25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/alz.13539","article-title":"Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET.","volume":"20","author":"Cogswell","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"9","key":"noi250056r26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","article-title":"Plasma phosphorylated tau 217 and A\u00df42\/40 to predict early brain A\u00df accumulation in people without cognitive impairment.","volume":"81","author":"Janelidze","year":"2024","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi250056r27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"577","key":"noi250056r28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc0655","article-title":"The cortical origin and initial spread of medial temporal tauopathy in Alzheimer\u2019s disease assessed with positron emission tomography.","volume":"13","author":"Sanchez","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"noi250056r29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3233\/JAD-170840","article-title":"18F-flortaucipir binding in choroid plexus: related to race and hippocampus signal.","volume":"62","author":"Lee","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"noi250056r30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease.","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement"},{"key":"noi250056r6","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198524847.001.0001","volume-title":"Analysis of Longitudinal Data","author":"Diggle","year":"2002"},{"key":"noi250056r9","author":"Willis","year":"2024"},{"key":"noi250056r13","doi-asserted-by":"crossref","unstructured":"Ossenkoppele? R, Salvad\u00f3? G, Janelidze? S, . Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology. Published online June 13, 2024. doi:10.1101\/2024.06.12.24308824","DOI":"10.1101\/2024.06.12.24308824"},{"key":"noi250056r21","unstructured":"Goodrich? B, Gabry? J, Crowther? M, Brilleman? S. rstanarm: Bayesian applied regression modeling via Stan. Published online 2024. Accessed July 31, 2025. https:\/\/mc-stan.org\/rstanarm\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2838121\/jamaneurology_insel_2025_oi_250056_1770138155.02751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:00:25Z","timestamp":1770652825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2838121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.2974","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}